Journal article
Clinically relevant concentrations of valproic acid modulate melatonin MT1 receptor, HDAC and MeCP2 mRNA expression in C6 glioma cells
Abstract
C6 glioma cells were treated with clinically relevant concentrations of valproic acid (0.5 or 1.0 mM) for 1-7 days and RT-PCR used to examine expression of the melatonin MT(1) receptor and selected epigenetic modulators. Valproic acid caused significant time-dependent changes in the mRNA expression of the melatonin MT(1) receptor, histone deacetylase (HDAC) 1, 2 and 3, and methyl CpG binding protein 2 (MeCP2). A structurally distinct HDAC …
Authors
Kim B; Castro LMR; Jawed S; Niles LP
Journal
European Journal of Pharmacology, Vol. 589, No. 1-3, pp. 45–48
Publisher
Elsevier
Publication Date
July 2008
DOI
10.1016/j.ejphar.2008.04.058
ISSN
0014-2999
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AnimalsBrain NeoplasmsCell Line, TumorDose-Response Relationship, DrugEnzyme InhibitorsEpigenesis, GeneticGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticGliomaHistone Deacetylase 1Histone Deacetylase 2Histone Deacetylase InhibitorsHistone DeacetylasesHydroxamic AcidsMethyl-CpG-Binding Protein 2RNA, MessengerRatsReceptor, Melatonin, MT1Repressor ProteinsReverse Transcriptase Polymerase Chain ReactionTime FactorsValproic Acid